VETRAMYCIN®-P forte Hrvatska - hrvatski - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

vetramycin®-p forte

medical intertrade d.o.o., sveta nedelja, hrvatska - prokain benzilpenicilin, dihidrostreptomicin, prednizolon i prokain hidroklorid - injekcijska suspenzija - goveda, pasa i mačaka

COMBICLAV Hrvatska - hrvatski - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

combiclav

norbrook laboratories (ireland) limited, rossmore industrial estate, monaghan, irska - amoksicilin (u obliku amoksicilin trihidrata) ; klavulanska kiselina (u obliku kalijevog klavulanata) ; prednizolon - intramamarna suspenzija, za krave u laktaciji - antibakterijske tvari za intramamarnu primjenu - goveda (krava u laktaciji)

Cabazitaxel Accord Europska Unija - hrvatski - EMA (European Medicines Agency)

cabazitaxel accord

accord healthcare s.l.u. - cabazitaxel - tumori prostate, Кастраци-uporan - antineoplastična sredstva - treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.

TETRA DELTA Hrvatska - hrvatski - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

tetra delta

zoetis b.v., podružnica zagreb za promidžbu, petra hektorovića 2, zagreb, hrvatska - novobiocin; neomicin; benzilpenicilinprokain ; dihidrostreptomicin; prednizolon - intramamarna suspenzija - goveda (krava u laktaciji)

CLAMOX LC Hrvatska - hrvatski - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

clamox lc

crida pharm s.r.l. intrarea vagonetului street, no. 2, bloc 101, ap. 47, sector 6, bukurešt, rumunjska - amoksicilin (u obliku amoksicilin trihidrata); klavulanska kiselina (u obliku kalijeva klavulanata); prednizolon - intramamarna suspenzija, za krave u laktaciji - goveda (krave u laktaciji)

Mastijet Fort, 200 mg + 250 mg + 2000 i.j. + 10 mg Hrvatska - hrvatski - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

mastijet fort, 200 mg + 250 mg + 2000 i.j. + 10 mg

intervet international bv – podružnica u rh, ivana lučića 2a, zagreb, rh - tetraciklinklorid; neomicin (u obliku neomicinsulfata); bacitracin; prednizolon - intramamarna suspenzija - goveda (krava u laktaciji)

Akeega Europska Unija - hrvatski - EMA (European Medicines Agency)

akeega

janssen-cilag international n.v. - abiraterone acetate, niraparib tosilate monohydrate - tumori prostate, Кастраци-uporan - antineoplastična sredstva - treatment of adult patients with prostate cancer.

Riximyo Europska Unija - hrvatski - EMA (European Medicines Agency)

riximyo

sandoz gmbh - rituksimab - lymphoma, non-hodgkin; arthritis, rheumatoid; microscopic polyangiitis; wegener granulomatosis - antineoplastična sredstva - riximyo is indicated in adults for the following indications:non-hodgkin’s lymphoma (nhl)riximyo is indicated for the treatment of previously untreated adult patients with stage iii-iv follicular lymphoma in combination with chemotherapy. riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy. riximyo monotherapy is indicated for treatment of adult patients with stage iii-iv follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. riximyo is indicated for the treatment of adult patients with cd20 positive diffuse large b cell non-hodgkin’s lymphoma in combination with chop (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage cd20 positive diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl)/burkitt leukaemia (mature b-cell acute leukaemia) (bal) or burkitt-like lymphoma (bll). chronic lymphocytic leukaemia (cll)riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. postoje samo ograničeni podaci o učinkovitosti i sigurnosti bolesnika prethodno liječenih monoklonsko antitijelo, uključujući rituksimab ili bolesne, vatrostalne standardnim tretmanima na prethodnu rituksimab + kemoterapija. cm. odjeljak 5. 1 za daljnje informacije. rheumatoid arthritisriximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (dmard) including one or more tumour necrosis factor (tnf) inhibitor therapies. rituksimab je pokazala da smanjuje brzinu progresije oštećenja zglobova kao što se mjeri x-ray i poboljšati fizičku funkciju, prilikom raspoređivanja u kombinaciji s metotreksatom. granulomatosis with polyangiitis and microscopic polyangiitisriximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (wegener’s) (gpa) and microscopic polyangiitis (mpa). riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active gpa (wegener’s) and mpa. pemphigus vulgarisriximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (pv).

Rixathon Europska Unija - hrvatski - EMA (European Medicines Agency)

rixathon

sandoz gmbh - rituksimab - lymphoma, non-hodgkin; arthritis, rheumatoid; leukemia, lymphocytic, chronic, b-cell; wegener granulomatosis; microscopic polyangiitis; pemphigus - antineoplastična sredstva - rixathon is indicated in adults for the following indications:non-hodgkin’s lymphoma (nhl)rixathon is indicated for the treatment of previously untreated adult patients with stage iii-iv follicular lymphoma in combination with chemotherapy. rixathon maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy. rixathon monotherapy is indicated for treatment of adult patients with stage iii-iv follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. rixathon is indicated for the treatment of adult patients with cd20 positive diffuse large b cell non-hodgkin’s lymphoma in combination with chop (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. rixathon in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage cd20 positive diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl)/burkitt leukaemia (mature b-cell acute leukaemia) (bal) or burkitt-like lymphoma (bll). kronične limfocitne leukemije (ХЛЛ)rixathon u kombinaciji s kemoterapijom što je prikazano za obradu bolesnika prethodno liječenih liječenje i relapsed/тугоплавким kroničnim лимфоцитарным. postoje samo ograničeni podaci o učinkovitosti i sigurnosti bolesnika prethodno liječenih monoklonsko antitijelo, uključujući rituksimab ili bolesne, vatrostalne standardnim tretmanima na prethodnu rituksimab + kemoterapija. cm. odjeljak 5. 1 za daljnje informacije. reumatoidni arthritisrixathon u kombinaciji s metotreksatom prikazana za liječenje odraslih bolesnika s teškim aktivnim reumatoidnim artritisom, koji su imali neadekvatan odgovor ili netoleranciju drugih bolesti дорабатывая anti-reumatskih lijekovi (dmards), uključujući jedan ili više faktora nekroze tumora (tnf) inhibitor terapija. rituksimab je pokazala da smanjuje brzinu progresije oštećenja zglobova kao što se mjeri x-ray i poboljšati fizičku funkciju, prilikom raspoređivanja u kombinaciji s metotreksatom. granulomatosis with polyangiitis and microscopic polyangiitisrixathon, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (wegener’s) (gpa) and microscopic polyangiitis (mpa). rixathon, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active gpa (wegener’s) and mpa. pemphigus vulgarisrixathon is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (pv).